Home Cart Sign in  
Chemical Structure| 75530-68-6 Chemical Structure| 75530-68-6

Structure of Nilvadipine
CAS No.: 75530-68-6

Chemical Structure| 75530-68-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nilvadipine is a potent calcium channel blocker with an IC50 of 0.03 nM.

Synonyms: FR34235; FK235; Nilvadipine, Escor, Nivadil, FR-34235, FK-235

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nilvadipine

CAS No. :75530-68-6
Formula : C19H19N3O6
M.W : 385.37
SMILES Code : O=C(C1=C(C#N)NC(C)=C(C(OC(C)C)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OC
Synonyms :
FR34235; FK235; Nilvadipine, Escor, Nivadil, FR-34235, FK-235
MDL No. :MFCD00867065
InChI Key :FAIIFDPAEUKBEP-UHFFFAOYSA-N
Pubchem ID :4494

Safety of Nilvadipine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

    Calcium channel, IC50:0.03 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02017340 Alzheimer's Disease Phase 3 Completed - France ... More >> Centre Hospitalier Universitaire d'Amiens (CHU Amiens) Amiens, France Centre Hospitalier Universitaire de Bethune (CH Bethune) Bethune, France Centre Hospitalier Universitaire de Caen (CHU Caen) Caen, France Centre Hospitalier Universitaire de Calais (CHU Calais) Calais, France Centre Hospitalier Universitaire de Lens (CHU Lens) Lens, France Centre Hospitalier Regional et Universitaire de Lille (CHRU Lille) Lille, France Centre Hospitalier Universitaire de Saint Philibert (GHICL) Lille, France Germany University of Ulm Ulm, Germany Greece "G. Papanicolaou" Hospital Athens, Greece "G.Papageorgiou" Hospital Athens, Greece AXEPA Hospital Athens, Greece Hungary Szeged University Szeged, Hungary Ireland University College Cork Cork, Ireland St James Hospital Dublin, Ireland Italy Hospital of Brescia Brescia, Italy Hospital Castellanza Castellanza, Italy Hospital of Genoa Genoa, Italy Hospital of Milan Milan, Italy Netherlands Hospital of Arnhem Arnhem, Netherlands Hospital of Maastricht Maastricht, Netherlands Hospital of Nijmegen Nijmegen, Netherlands Sweden Gothenburg Univeristy Gothenburg, Sweden United Kingdom Kings College London London, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.97mL

2.59mL

1.30mL

25.95mL

5.19mL

2.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Ozawa Y, Hayashi K, et al. Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. J Cardiovasc Pharmacol. 1999 Feb;33(2):243-7.

[2]Nomoto A, Mutoh S, et al. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis. 1988 Aug;72(2-3):213-9.

[3]Morin A, Mouzon B, Ferguson S, Paris D, Browning M, Stewart W, Mullan M, Crawford F. Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI. Acta Neuropathol Commun. 2020 Oct 19;8(1):166

[4]Nomoto A, Hirosumi J, Sekiguchi C, Mutoh S, Yamaguchi I, Aoki H. Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery. Atherosclerosis. 1987 Apr;64(2-3):255-61

[5]Sugawara H, Tobise K, Kikuchi K. Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Hypertens Res. 1996 Dec;19(4):223-8

[6]Iwasaki K, Egashira N, Takagaki Y, Yoshimitsu Y, Hatip-Al-Khatib I, Mishima K, Fujiwara M. Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. Biol Pharm Bull. 2007 Apr;30(4):698-701

[7]Morin A, Mouzon B, Ferguson S, Paris D, Saltiel N, Lungmus C, Mullan M, Crawford F. Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI. Front Aging Neurosci. 2018 Oct 11;10:292

 

Historical Records

Categories